viewRestaurant Group PLC

The Restaurant Group rewarded by strong strategy, reckons UBS


Strong strategic moves by The Restaurant Group (LON:RTN) amid consumer pressure has been reflected in a robust financial performance, reckons analyst Isabel Green at UBS, which rates the stock a "buy".

In a note, the research arm of the financial group said it was targeting a price of 340 pence for the shares.

The firm operates almost 400 restaurants and pubs and its main brand names are Frankie & Benny's, Chiquito and Garfunkel's. It also runs concessions in seven airports.

Green said that the firm saw robust like-for-like sales growth of three percent in the first half, adding that the two percent growth it was seeing so far in the second was "encouraging".

"We believe this reflects its strong strategic positioning with defensive out of town locations, and continued avoidance of heavy discounting sales tactics."

The analyst went on to say that The Restaurant Group's new site numbers continued to improve with 25-26 sites expected this year and full year earnings for 2012 expected to at least match this.

"Management has taken the opportunity to trim the tail of the estate, with nine closures announced. Six of these are strategic closures and three operational. There may be three - four additional closures in H2, which we see as prudent in the current environment," said Green.

Quick facts: Restaurant Group PLC

Price: 145.4 GBX

Market: LSE
Market Cap: £714.64 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

5 hours, 52 minutes ago

2 min read